Samsung Biologics, AstraZeneca shutting down their joint venture Archigen Biotech
IndustryMay 24, 2022
Samsung Biologics Co., the biotech arm of South Korea's Samsung Group, is shutting down its joint venture with multinational pharmaceutical company AstraZeneca Plc., a company official said Tuesday, due to the suspension of the development of a biosimilar product. The move came two months after Samsung Biologics' board approved the liquidation of Archigen Biotech Ltd., a 50-50 joint venture set up with AstraZeneca, in 2014. Archigen Biotech was responsible for developing SAIT101, a bio